On 21 February 2025, the FDA announced that the US semaglutide injection product shortage has resolved, such that semaglutide can now be removed from the drug shortages list. The FDA has confirmed it will take action from 22 April 2025 against state-licensed pharmacies which sell compounded versions of the drug and from 22 May 2025 against outsourcing facilities which compound, distribute or sell semaglutide copies.
Semaglutide injection products, namely Novo Nordisk’s popular weight-loss drug Wegovy® and its diabetes drug Ozempic®, were first added to the FDA’s drug shortages list in March 2022 and August 2022, respectively. While it was announced in October 2024 that all doses of Wegovy® and Ozempic® were available in the US, the FDA has continued to monitor the availability of the drugs. Based on information provided by Novo Nordisk, the FDA has now concluded that Novo Nordisk’s supply of semaglutide is currently meeting or exceeding demand and it has sufficient reserves to meet or exceed projected demand.